专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20160129077A1 Use of recombinant ganoderma immunoregulatory protein (rLZ-8) in preparation of drug for treating melanoma 审中-公开
标题翻译：使用重组灵芝免疫调节蛋白（rLZ-8）制备治疗黑色素瘤的药物
公开(公告)号：US20160129077A1
公开(公告)日：2016-05-12
申请号：US14907263
申请日：2014-06-13
申请人： Xitian Zhang , Fei Sun
发明人： Xitian Zhang , Fei Sun , Chongyang Liang
IPC分类号： A61K38/16
CPC分类号： A61K38/16
摘要： A use of recombinant ganoderma immunoregulatory protein (rLZ-8) in a preparation of a drug for treating melanoma is disclosed. By establishing experimental animal models of orthotopic tumors and metastatic tumors, an anti-tumor effect of the rLZ-8 is researched, which indicates that the rLZ-8 significantly inhibits a growth of the orthotopic tumors of the melanoma and a formation of metastases of the melanoma.
摘要翻译：公开了重组灵芝免疫调节蛋白（rLZ-8）在制备治疗黑素瘤药物中的应用。通过建立原位肿瘤和转移性肿瘤的实验动物模型，研究了rLZ-8的抗肿瘤作用，表明rLZ-8显着抑制黑素瘤原位肿瘤的生长，形成转移瘤黑色素瘤

2. 发明申请

US20110009597A1 RECOMBINANT GANODERMA LUCIDIUM IMMUNOMODULATORY PROTEIN (rLZ-8) AND USES THEREOF 审中-公开
标题翻译：重组GANODERMA LUCIDIUM免疫培养基蛋白（rLZ-8）及其用途
公开(公告)号：US20110009597A1
公开(公告)日：2011-01-13
申请号：US12829653
申请日：2010-07-02
申请人： Fei SUN , Xitian ZHANG
发明人： Fei SUN , Xitian ZHANG
IPC分类号： C07K14/00
CPC分类号： C07K14/37 , A61K38/00 , C07K14/375 , Y02A50/483
摘要： Provided are the use of the recombinant Ganoderma lucidium immunomodulatory protein (rLZ-8) for the manufacturing of a medicament for antitumor, increasing leukocyte and inhibiting immunological rejection and the pharmaceutical composition comprising the rLZ-8 protein, wherein the rLZ-8 protein is expressed from pichia yeast.
摘要翻译：提供了重组灵芝免疫调节蛋白（rLZ-8）用于制造用于抗肿瘤，增加白细胞和抑制免疫排斥的药物的组合物，以及包含rLZ-8蛋白质的药物组合物，其中rLZ-8蛋白质被表达来自毕赤酵母。

3. 发明申请

US20150329601A1 Methoxypolyethyleneglycol succinimidyl propionate modified recombinant Ganoderma Lucidum immunoregulatory protein, preparing method and application thereof 审中-公开
标题翻译：甲氧基聚乙二醇丙酸琥珀酰亚胺酯改性重组灵芝免疫调节蛋白，其制备方法及应用
公开(公告)号：US20150329601A1
公开(公告)日：2015-11-19
申请号：US14814356
申请日：2015-07-30
申请人： Xitian Zhang , Fei Sun
发明人： Xitian Zhang , Fei Sun , Chongyang Liang
IPC分类号： C07K14/37
CPC分类号： C07K14/37 , A61K38/00 , A61K38/16 , A61K47/60 , C07K14/375
摘要： Methoxypolyethyleneglycol succinimidyl propionate modified recombinant Ganoderma Lucidum immunoregulatory protein, a preparing method and applications thereof are provided, including: the mPEG-SPA modified rLZ-8; the method for preparing the mPEG-SPA modified rLZ-8 comprising: feeding the rLZ-8 dimer and the mPEG-SPA with the molar ratio of 1:1-1:6 into a 0.1M phosphate buffer with pH 5.0-pH 8.0, and stirring by a magnetic stirrer at a room temperature for 1.0-2.5 h, purifying the product for obtaining a modification product with a purity of 98%; and applications of the mPEG-SPA modified rLZ-8 in preparation of medicine for treating leukopenia due to chemotherapy. Advantages are as follows: the method for preparing the mPEG-SPA modified rLZ-8 is simple, and the product is identical; a half-life of the mPEG-SPA modified rLZ-8 is significantly longer than the half-life of unmodified rLZ-8 (illustrated in the FIG. 2); a minimum effective dosage and time for treating leucopenia are also improved.
摘要翻译：提供了甲氧基聚乙二醇琥珀酰亚胺基丙酸酯改性重组灵芝免疫调节蛋白，其制备方法及应用，包括：mPEG-SPA修饰的rLZ-8; 制备mPEG-SPA修饰的rLZ-8的方法包括：将rLZ-8二聚体和mPEG-SPA以1:1-1:6的摩尔比进料到pH 5.0-pH 8.0的0.1M磷酸盐缓冲液中，并用磁力搅拌器在室温下搅拌1.0-2.5小时，纯化产物，得到纯度为98％的改性产物; 以及mPEG-SPA修饰的rLZ-8在化疗药物治疗白细胞减少症药物中的应用。优点如下：制备mPEG-SPA改性rLZ-8的方法简单，产品相同; mPEG-SPA修饰的rLZ-8的半衰期明显长于未修饰的rLZ-8（如图2所示）的半衰期; 治疗白细胞减少症的最小有效剂量和时间也得到改善。

4. 发明申请

US20110033556A1 Natural Pharmaceutical Preparations for Increasing Albumin 有权
标题翻译：用于增加白蛋白的天然药物制剂
公开(公告)号：US20110033556A1
公开(公告)日：2011-02-10
申请号：US12793958
申请日：2010-06-04
申请人： Zheming Jin , Xitian Zhang
发明人： Zheming Jin , Xitian Zhang
IPC分类号： A61K36/481 , A61K36/282 , A61K36/18 , A61K36/28 , A61K35/56 , A61K36/258 , A61K36/482 , A61K36/484 , A61K36/605 , A61K36/8969 , A61K36/815 , A61K36/074 , A61K36/65 , A61K36/537 , A61K36/894 , A61K36/748 , A61K36/804 , A61K35/64 , A61K36/906 , A61K36/884 , A61K36/23 , A61K36/704 , A61K36/90 , A61K36/355 , A61K36/81 , A61K36/428 , A61K36/536 , A61K36/539 , A61K35/38 , A61K36/16 , A61K36/535 , A61K36/71 , A61K36/63 , A61P31/14 , A61P31/20 , A61P31/06 , A61P31/18 , A61P29/00 , A61P1/16
CPC分类号： A61K36/00
摘要： A natural pharmaceutical preparation for treating hypoproteinemia, includes at least one member selected from the group consisting of a drug of increasing human serum albium, a drug of improving and enhance immunity, a drug of treating hepatitis B, a drug of treating Hepatitis C, a drug of treating acquired immune deficiency syndrome (AIDS), a drug of treating Tuberculosis, a drug of treat Fibrosis, a drug of treating hydrothorax, a drug of easing pain, a drug of stopping diarrhea, a drug of arresting coughing, a drug of reducing inflammation, and a drug of increasing urine.
摘要翻译：一种用于治疗低蛋白血症的天然药物制剂，包括至少一种选自增加人血清白蛋白的药物，改善和增强免疫力的药物，治疗乙型肝炎的药物，治疗丙型肝炎的药物，a 治疗获得性免疫缺陷综合征（AIDS）的药物，治疗结核病的药物，治疗性纤维化药物，治疗胸水的药物，缓解疼痛的药物，停止腹泻的药物，止咳药的药物减少炎症，增加尿液的药物。

5. 发明授权

US09789158B2 Applications of recombined Ganoderma lucidum immunoregulation protein in preparing drugs for treating tissue fibrosis 有权
公开(公告)号：US09789158B2
公开(公告)日：2017-10-17
申请号：US15101395
申请日：2014-06-13
申请人： Xitian Zhang , Fei Sun
发明人： Xitian Zhang , Fei Sun , Chongyang Liang
IPC分类号： A61K49/00 , A61K39/00 , A61K45/00 , A61K38/16 , A61K36/074
CPC分类号： A61K38/16 , A61K36/074
摘要： Applications of recombined ganoderma lucidum immunoregulation protein (rLZ-8) in preparing drugs for treating tissue fibrosis are provided.

6. 发明授权

US08202555B2 Natural pharmaceutical preparations for increasing albumin 有权
标题翻译：用于增加白蛋白的天然药物制剂
公开(公告)号：US08202555B2
公开(公告)日：2012-06-19
申请号：US12793958
申请日：2010-06-04
申请人： Zheming Jin , Xitian Zhang
发明人： Zheming Jin , Xitian Zhang
IPC分类号： A01N65/00
CPC分类号： A61K36/00
摘要： A natural pharmaceutical preparation for treating hypoproteinemia, includes at least one member selected from the group consisting of a drug of increasing human serum albium, a drug of improving and enhance immunity, a drug of treating hepatitis B, a drug of treating Hepatitis C, a drug of treating acquired immune deficiency syndrome (AIDS), a drug of treating Tuberculosis, a drug of treat Fibrosis, a drug of treating hydrothorax, a drug of easing pain, a drug of stopping diarrhea, a drug of arresting coughing, a drug of reducing inflammation, and a drug of increasing urine.
摘要翻译：一种用于治疗低蛋白血症的天然药物制剂，包括至少一种选自增加人血清白蛋白的药物，改善和增强免疫力的药物，治疗乙型肝炎的药物，治疗丙型肝炎的药物，a 治疗获得性免疫缺陷综合征（AIDS）的药物，治疗结核病的药物，治疗性纤维化药物，治疗胸水的药物，缓解疼痛的药物，停止腹泻的药物，止咳药的药物减少炎症，增加尿液的药物。

7. 发明申请

US20050019378A1 Transdermal drug delivery system of strychnine, brucine, securinine and their salts 审中-公开
标题翻译：士的宁经皮药物输送系统，草甘膦，证明他们的盐及其盐
公开(公告)号：US20050019378A1
公开(公告)日：2005-01-27
申请号：US10496309
申请日：2002-10-18
申请人： Xitian Zhang
发明人： Xitian Zhang
IPC分类号： A61K9/06 , A61K9/08 , A61K9/12 , A61K9/70 , A61K31/439 , A61K31/475 , A61K47/06 , A61K47/16 , A61K47/46 , A61P1/00 , A61P7/06 , A61P11/00 , A61P15/00 , A61P17/00 , A61P19/02 , A61P21/04 , A61P25/00 , A61P25/02 , A61P25/18 , A61P27/02 , A61K31/46
CPC分类号： A61K9/0014 , A61K9/7023 , A61K47/06 , Y02A50/465
摘要： Strychnine, brucine (A) and securinine (B) are a group of natural drugs for central excitation. Because their oral dose or injection dose is close to the half lethal dose, the drugs, with a great toxic side effect, may be lethal if improperly used. The invention is characterized by using the transdermal drug delivery system as a substitute for the oral or injection dosage form to directly act on the local nervous system through the skin, avoiding the toxic side effect caused by drugs directly entering the blood circulating system. The dose through cutaneous absorption is far lower than the oral or injection dose, so it has a much higher safety and a longer acting effect. The transdermal drug delivery system is useful for the treatment of central or peripheral neural paralysis and other nervous system related diseases.
摘要翻译：士的宁，胭脂碱（A）和证明（B）是一组中枢激发的天然药物。由于其口服剂量或注射剂量接近半致死剂量，如果使用不当，具有很大毒副作用的药物可能是致死的。本发明的特征在于使用透皮药物递送系统作为口服或注射剂型的替代物，通过皮肤直接作用于局部神经系统，避免直接进入血液循环系统的药物引起的毒副作用。通过皮肤吸收的剂量远远低于口服或注射剂量，因此具有更高的安全性和更长的作用效果。透皮药物递送系统可用于治疗中枢性或周围神经麻痹和其他与神经系统相关的疾病。

8. 发明申请

US20220177588A1 SINGLE DOMAIN ANTIBODY AND DERIVATIVE PROTEINS THEREOF AGAINST CTLA4 有权
公开(公告)号：US20220177588A1
公开(公告)日：2022-06-09
申请号：US17369169
申请日：2021-07-07
申请人： XITIAN ZHANG , XIN ZHANG , SUZHOU ALPHAMAB CO., LTD.
发明人： Ting Xu , Xiaoxiao Wang , Jie Li , Haiyan Wu , Li Gao , Qian Chu , Yu Bai
IPC分类号： C07K16/28 , A61P35/00 , A61K39/395 , C07K16/22 , C07K16/32 , C12N15/70
摘要： The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.

9. 发明授权

US11091549B2 Single domain antibody and derivative proteins thereof against CTLA4 有权
公开(公告)号：US11091549B2
公开(公告)日：2021-08-17
申请号：US16302583
申请日：2017-05-19
申请人： SUZHOU ALPHAMAB CO., LTD. , XITIAN ZHANG , XIN ZHANG
发明人： Ting Xu , Xiaoxiao Wang , Jie Li , Haiyan Wu , Li Gao , Qian Chu , Yu Bai
IPC分类号： C07K16/00 , C07K16/28 , A61P35/00 , A61K39/395 , C07K16/22 , C07K16/32 , C12N15/70 , A61K39/00
摘要： The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against CTLA4. In particular, the present invention discloses a CTLA4 binding protein and the use thereof, especially the use for treating and/or preventing CTLA4 relevant diseases such as tumor.

10. 发明申请

US20190352345A1 Mutants of recombinant immunoregulatory protein of Ganoderma lucidum and applications thereof 审中-公开
公开(公告)号：US20190352345A1
公开(公告)日：2019-11-21
申请号：US16462941
申请日：2018-03-14
申请人： Xitian Zhang , Fei Sun , Xin Zhang
发明人： Fei Sun , Chongyang Liang
IPC分类号： C07K14/375 , A61P35/00 , A61P35/04
摘要： Mutants of recombinant immunoregulatory protein of Ganoderma lucidum (rLZ-8) and applications thereof are provided. It is found by the present invention that: an anti-EGFR (epidermal growth factor receptor) domain exists in a structure of the rLZ-8; particularly, the domain through positive potential characteristics thereof induces a killing effect to an abnormal EGFR-expressed tumor. Based on the above scientific discovery, with utilizing computational simulation technology, the mutants of the rLZ-8, having better antitumor effects, are obtained.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式